Cispoly Secures Nearly RMB 100 Million in Pre-A Financing to Advance Gynecological Cancer Early Screening

VCBeat (WeChat ID: vcbeat) has learned that Cispoly announced the completion of its Pre-A financing round, amounting to nearly RMB 100 million.Led by Shanlan Capital, with participation from renowned industry institutions, and Probe Capital serving as the exclusive financial advisor. The proceeds from this round of financing will be primarily used for team building, product regulatory approval, pipeline development, clinical collaborations, and initial market expansion.

Previously, cispoly completed its angel round of financing in October 2020, exclusively led by ZhenFund. Regarding the consecutive favor from investment institutions,Dr. Liu Pei, Founder of CispolyIn response, the company stated: “We thank both new and existing shareholders for their recognition and support of cispoly. cispoly Bio has remained committed to women’s health and independent innovation. In particular, we have been dedicated to conducting original research in gynecologic oncology, carrying out cross-sectional collaborative studies with multiple top-tier hospitals. We have launched a multicenter cohort study on methylation-based comprehensive gynecologic cancer screening in partnership with Peking Union Medical College Hospital, while actively advancing our pipeline.”

Cispoly is a high-tech enterprise dedicated to innovative biotechnology and women’s health, striving to become a leader in the early diagnosis of gynecological tumors. Leveraging its proprietary technologies and patent-protected biomarkers, the company has developed early diagnostic products for cervical cancer, ovarian cancer, endometrial cancer, and other gynecological malignancies, filling a critical gap in this field. Currently, Cispoly has pioneered a nationwide, multicenter, prospective study focused on cervical cancer, marking China’s first prospective research project utilizing DNA methylation for gynecological tumors. The study has already enrolled 30,000 patients.

It is understood that the vast majority of cancer screening products currently on the market in China have only completed retrospective studies. However, multicenter, large-cohort prospective trials are a prerequisite for such products to be approved for market entry and used as population-level screening tools. Cispoly has adopted a three-step strategy comprising “retrospective study–prospective study–multicenter cohort study.” Within less than a year of its establishment, the company has completed both the retrospective and prospective studies for its early screening and diagnostic products for gynecological tumors. Meanwhile, the prospective multicenter cohort study on the use of DNA methylation for cervical lesion screening has also been launched.

Regarding the investment in cispoly,Nie Hongxin, Managing Partner at Shanlan Capital“It is crucial to conduct early screening and diagnosis of cancer to improve the effectiveness of cancer treatment. However, there is still a lack of products in the field of gynecological oncology that fully meet clinical needs. The methylation detection technology adopted by cispoly is the most promising method to address the pain points of existing screening methods for gynecological tumors. Meanwhile, the company strictly follows high-standard clinical research paths during product development, laying a solid foundation for product performance and subsequent large-scale commercial applications. Shanlan Capital has great confidence in the leading R&D capabilities and efficient execution of cispoly's founding team. In the future, Shanlan Capital will fully leverage its industrial resources and advantages to help the company become a leader in China’s early cancer screening industry.”

Existing Shareholders of cispolyDr. Chen Gaopeng, Vice President of ZhenFundHe also acknowledged, “Early cancer screening has become an industry hotspot in recent years. While HPV and TCT testing for cervical cancer offer sufficient sensitivity, their lack of specificity has led to anxiety and overtreatment among many women, causing numerous clinical challenges. Cispoly’s methylation-based biomarkers effectively address this issue, enabling the detection and differentiation of ovarian and endometrial cancers, with minimal limitations imposed by sampling methods. Beyond our optimism about this sector, Dr. Liu Pei’s team has delivered many pleasant surprises, demonstrating exceptional execution capabilities and comprehensive expertise. We look forward to Cispoly achieving further remarkable milestones.”

Founded in 2020, cispoly operates a 900-square-meter GMP-certified production facility and an 800-square-meter R&D laboratory at the Daxing Biomedical Base. The company focuses on the research and development, manufacturing, and sales of early diagnostic products for gynecological cancers and related automated detection equipment. cispoly holds intellectual property rights for its leading methylation detection technology and multiple biomarkers, and it aims to explore further opportunities in the field of women’s health.

Shanlan Capital is a professional investment fund focused on early-stage and growth-stage investments in the healthcare industry. It targets high-growth subsectors such as biopharmaceuticals, medical devices (including in vitro diagnostics and gene technologies, minimally invasive interventional devices, implantable devices, minimally invasive surgical instruments, and medical robots), and healthcare services. The firm has invested in more than 20 leading healthcare companies. Shanlan Capital’s core team comprises founders of publicly listed healthcare companies, as well as professionals specializing in financial and strategic investment. The team provides value-added services to portfolio companies across various dimensions, assisting them in integrating advanced international technologies and establishing global operational concepts and standards, thereby supporting their continuous innovation and development.

ZhenFund is an early-stage investment firm co-founded by Mr. Xu Xiaoping and Mr. Wang Qiang in partnership with Sequoia Capital China in 2011. With total assets under management exceeding $1 billion, ZhenFund actively seeks out the most exceptional entrepreneurial teams and epoch-defining investment opportunities across sectors such as the internet, mobile internet, future technologies, artificial intelligence, enterprise services, healthcare, mass consumer markets, and education. The fund has invested in more than 700 startups, including Yitu Technology, XtalPi, Shuidi Huzhu, and Xiaohongshu (Little Red Book), with over 50 portfolio companies achieving exits through various channels.